Oncotarget
Press Release: Genomic Alterations Predictive of Poor Clinical Outcomes in Pan-cancer
Oct 4, 2022
Researchers Crystal S. Seldon, Karthik Meiyappan, Hannah Hoffman, and others discussed genomic alterations in pan-cancer predicting poor clinical outcomes. They explored associations of common genomic alterations across 28 cancers, emphasizing the importance of tailored treatment strategies for patients with specific genomic alterations.
04:27
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Common genomic alterations impact clinical outcomes in Pan Cancer cohorts.
- Identifying specific genomic alterations can guide treatment decisions and enrich clinical trials in Pan Cancer.
Deep dives
Genomic Alterations Predict Poor Clinical Outcomes
The research paper published in Enco Targets volume 13 discusses the impact of genomic alterations on clinical outcomes in Pan Cancer cohorts. Researchers analyzed data from Pan Cancer TCGA and MSK impact cohorts to identify common genomic alterations associated with poor outcomes. TP53 mutations, Mute 31, CDK N2A deletion, PTEN deletion, and MYC amplification were found to independently predict worse progression-free survival and overall survival. These alterations suggest the need for more aggressive treatment strategies, with clinical trials aimed at identifying treatment options for patients with these specific genomic alterations.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
